HSV vector-mediated gene delivery to the central nervous system.
The efficient and targeted transfer of genes is the goal of gene therapy. In the central nervous system (CNS), this is challenging due in part to the exquisite anatomy of the brain. Herpes simplex virus (HSV) vectors are particularly amenable to CNS therapies as they are capable of transducing a variety of cells, have a large transgene capacity and can exist as either oncolytic or non-immunogenic vectors. The versatility of this vector platform and its potential molecular therapeutic use in two CNS disorders, Alzheimer's disease and malignant brain tumors, will be discussed.
Maguire-Zeiss
K A
KA
Department of Neurology, University of Rochester School of Medicine and Dentistry, NY 14642, USA.
Bowers
W J
WJ
Federoff
H J
HJ
D000544:Alzheimer Disease / Q000628:therapy; D016229:Amyloid beta-Peptides / Q000235:genetics / Q000276:immunology; D000818:Animals; D001932:Brain Neoplasms / Q000628:therapy; D002490:Central Nervous System / Q000378:metabolism; D002493:Central Nervous System Diseases / Q000628:therapy*; D003131:Combined Modality Therapy; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends; D005822:Genetic Vectors; D006801:Humans; D011355:Prodrugs / Q000627:therapeutic use; D018139:Simplexvirus / Q000235:genetics*; D014614:Vaccines, Synthetic / Q000627:therapeutic use
D016229:Amyloid beta-Peptides; D011355:Prodrugs; D014614:Vaccines, Synthetic